INFLECTRA® (Infliximad-dyyb) is a Remicade biosimilar medication used to treat various autoimmune diseases.
INFLECTRA® is manufactured by Pfizer.
Administration and Dosage:
Administration of INFLECTRA® follows an induction regimen of 3 intravenous infusions at week 0, 2, and 6 followed by a maintenance infusion, once every 8 weeks.
Common Side Effects:
The more common side effects of INFLECTRA® include increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.
More Information:
Please read the full Prescribing Information for INFLECTRA® and discuss any questions you have with your doctor.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
Indication:
INFLECTRA® is indicated to treat:
- Crohn’s Disease
- Ulcerative Colitis
- Pediatric Ulcerative Colitis
- Pediatric Crohn’s Disease
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
